News for bluebird bio, Inc. (BLUE)

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ('Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer.

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that Denice M. Torres has been elected to the company's Boa

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Bluebird bio (BLUE) has officially completed its acquisition by funds associated with Carlyle and SK Capital Partners. As a result, the company's common stock i

bluebird bio (NASDAQ: BLUE) (”œbluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds mana

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have successfully completed the tender offer for bluebird bio, Inc.

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have successfully completed the tender offer for bluebird bio, Inc. (NASDAQ:BLUE) to acquire all outstanding common stock. With a value of either $3.00 per share plus a contingent value right or $5.00 per share in cash, the transaction […]

Bluebird bio's forthcoming acquisition offers shareholders two different payout options. Analysts present a strong upside in stock pricing, reflecting s

Carlyle (NASDAQ: CG) (”œCarlyle”), SK Capital Partners, LP (”œSK Capital”) and Beacon Parent Holdings, L.P. (”œParent”) today announced that the tende

Carlyle (CG) and SK Capital Partners successfully complete tender offer for bluebird bio (BLUE). 59.8% of bluebird bio's outstanding shares tendered by

bluebird bio, Inc. (NASDAQ: BLUE) (”œbluebird” or ”œthe Company”) today reminds all stockholders to promptly tender their shares into the tender offer by

bluebird bio, Inc. (BLUE) urges stockholders to tender shares for acquisition by Carlyle and SK Capital by May 29, 2025. The amended agreement o

bluebird bio faces imminent bankruptcy unless a deal closes. Learn more about the current deal and my recommendation of BLUE stock.

Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement. Under the terms of the amended agreement, Bluebird stockholders can elect to receive either the original offer of $3.00 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share in cash. The amended offer price provides

Bluebird Bio (BLUE) has revised its agreement with SK Capital Partners, allowing shareholders to choose between two payment options. Under the new terms, shareh

bluebird bio, Inc. (Nasdaq: BLUE) (”œbluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the

bluebird bio, Inc. (Nasdaq: BLUE) urges stockholders to tender shares by May 12, 2025, deadline. The acquisition by Carlyle and SK Capital is contingent

bluebird bio, Inc. (NASDAQ: BLUE) (”œbluebird” or ”œthe Company”), Carlyle (NASDAQ: CG) (”œCarlyle”), SK Capital Partners, LP (”œSK Capital”) and B

Bluebird Bio (BLUE) has announced that it has secured all necessary regulatory approvals for its acquisition by Carlyle and SK Capital Partners, along with Beac